Teiko Sumiyoshi

1.5k citations

28 papers · 549 indexed · h-index 14

Impact in

Oncology top 10%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Hematology top 10%
- Multiple Myeloma Research and Treatments

Papers in

Oncology 16
- Cancer Immunotherapy and Biomarkers 6
- CAR-T cell therapy research 4
- Colorectal Cancer Treatments and Studies 4
Hematology 6
- Multiple Myeloma Research and Treatments 5

Co-authors: Donald B. Kohn Mark R. Lackner Hartmut Koeppen Garret M. Hampton Priti S. Hegde Erica Schleifman Rachel Tam A. Clay Clark
Journals: Blood (6 papers)PLoS ONE (3 papers)Molecular Therapy (2 papers)Journal of Clinical Oncology (2 papers)Cancer Research (2 papers)
Partner nations: United States Australia Canada

In The Last Decade

Teiko Sumiyoshi

26 papers receiving 532 citations

Peers

Countries citing papers authored by Teiko Sumiyoshi

Since Specialization

Citations

This map shows the geographic impact of Teiko Sumiyoshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teiko Sumiyoshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teiko Sumiyoshi more than expected).

Fields of papers citing papers by Teiko Sumiyoshi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teiko Sumiyoshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teiko Sumiyoshi. The network helps show where Teiko Sumiyoshi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Teiko Sumiyoshi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Teiko Sumiyoshi Line = papers co-authored together Teiko Sumiyoshi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Bgb-16673, a Selective BTK Degrader, Exhibits Deeper Inhibition of Cancer Cell Signaling Pathways and Better Efficacy in MCL Models Blood ·Haitao Wang, Qiming Zhou, Li Lin, Weiwei Song, Shuang Peng, Xiangmei Chen, Linlin Xu, Teiko Sumiyoshi, Wei Jin, Zhirong Shen	2024	0
2	Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma SHILAP Revista de lepidopterología ·Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick J. Twomey, Voleak Choeurng, Junyi Li, Robert L. Hendricks, Shannon M. Ruppert, Teiko Sumiyoshi, Karen K. Miller, Eunpi Cho, Fredrik Schjesvold	2023	16
3	CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology ·Ravi Vij, N R Gillham, Suzanne Trudel, Alice Chinghsuan Chang, Jiangeng Huang, Divya Samineni, Teiko Sumiyoshi, Jennifer J. Tsai, Tiffany Wong, Simon J. Harrison	2022	6
4	A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Blood ·Torben Plesner, Simon J. Harrison, Hang Quach, Cindy H. Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert L. Hendricks, Teiko Sumiyoshi, Karen Miller, M. Oky Fardian Gafari, Fredrik Schjesvold	2021	10
5	Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma Blood ·Adam D. Cohen, Simon J. Harrison, Amrita Krishnan, Rafaël Fonseca, Peter A. Forsberg, Andrew Spencer, Jesús G. Berdeja, Jacob P. Laubach, Lewis Tzu-Ching Lu, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M. Fine, Suzanne Trudel	2020	65
6	Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma Blood ·Rin Nakamura, 杨娟, Francisco De Sola, Hartmut Koeppen, Anjali Vaze, Suzanne Trudel, Andrew Spencer, Simon J. Harrison, Adam D. Cohen, Bernard M. Fine, Lewis Tzu-Ching Lu, James Cooper, Teiko Sumiyoshi	2020	10
7	A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer Clinical Cancer Research ·Robert Piskol, Ling Huw, Ismail Sergin, Jialiang Kang, Zora Modrušan, Doris Kim, Noelyn M. Kljavin, Rachel Tam, Rajesh Patel, 阎思慧, Elicia Penuel, Xueping Qu, Hartmut Koeppen, Teiko Sumiyoshi, Frédéric J. de Sauvage, Mark R. Lackner, Felipe de Sousa e Melo, Omar Kabbarah	2019	40
8	Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer PLoS ONE ·Willemijn S.M.E. Theelen, Thomas Kuilman, Katja Schulze, Wei Zou, Oscar Krijgsman, Dennis Peters, Sten Cornelissen, Kim Monkhorst, Everettz Zimmerman, Teiko Sumiyoshi, Lukas C. Amler, Stefan M. Willems, J. L. G. Blaauwgeers, Carel J.M. van Noesel, Daniel S. Peeper, Michel M. van den Heuvel, Marcin Kowanetz	2019	9
9	Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology npj Precision Oncology ·Kwame Okrah, Somayeh S. Tarighat, 春雄林, Hartmut Koeppen, Marie-Claire Wagle, Guanxun Cheng, سهيلة دهماني, Anindya Dey, Caio Cavalcante Dos Santos, Teiko Sumiyoshi, Zineb Mounir, Craig Cummings, Garret M. Hampton, Lukas C. Amler, Jane Fridlyand, Priti S. Hegde, Shannon J. Turley, Mark R. Lackner, Simon Donck	2018	41
10	The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population npj Breast Cancer ·Timothy R. Wilson, Jianjun Yu, Xuyang Lu, Jill M. Spoerke, Yuanyuan Xiao, Carol O’Brien, Heidi Savage, Ling‐Yuh Huw, Wei Zou, Hartmut Koeppen, William F. Forrest, Jane Fridlyand, Ling Fu, Rachel Tam, Erica Schleifman, Teiko Sumiyoshi, Luciana Molinero, Garret M. Hampton, Joyce O’Shaughnessy, Mark R. Lackner	2016	25
11	Abstract 1553: Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN] Cancer Research ·Elicia Penuel, Amy V. Kapp, Ingrid Ameyalli Hernández-Barrios, Rachel Tam, Teiko Sumiyoshi, Chaitra Marathe, Susan Sa, Franklin Peale, Mark R. Lackner, Scott N. Holden, Tanguy Y. Seiwert, Andrea Pirzkall	2015	2
12	Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples Breast Cancer Research and Treatment ·Timothy R. Wilson, Yuanyuan Xiao, Jill M. Spoerke, Jane Fridlyand, Hartmut Koeppen, Yexinghan Hu, Ling Huw, Grigore Otetelişanu, X. F. Li, Erica Schleifman, Rupal Desai, Ling Fu, Teiko Sumiyoshi, Joyce O’Shaughnessy, Garret M. Hampton, Mark R. Lackner	2014	21
13	Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel PLoS ONE ·Erica Schleifman, Rachel Tam, Rajesh Patel, A Quiñonero Díaz, Teiko Sumiyoshi, Ling Fu, Rupal Desai, De. Auteur du texte Drulhe, Thomas W. Myers, R. M. Lazo, E. J. Smith, Rajiv Raja	2014	12
14	Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers PLoS ONE ·Erica Schleifman, Rupal Desai, Jill M. Spoerke, Yuanyuan Xiao, María Lucena de Ustáriz, Grigore Otetelişanu, Carol O’Brien, R. D. Patel, Teiko Sumiyoshi, Ling Fu, S. Heisterkamp, Hartmut Koeppen, Timothy R. Wilson, Rajiv Raja, Garret M. Hampton, Mark R. Lackner	2014	30
15	Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (UBC) Yuanyuan Xiao, Christina Rabe, Marcin Kowanetz, Thomas Powles, Nicholas J. Vogelzang, Daniel P. Petrylak, Yohann Loriot, Mitchell Denker, Rin Nakamura, Qun Wu, Teiko Sumiyoshi, Zachary Boyd, D. Menif, Xiaodong Shen, Gregg Fine, Daniel S. Chen, Priti S. Hegde	2014	1
16	Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology ·Joyce O’Shaughnessy, Timothy R. Wilson, Maren K. Levin, S. V. Mihovski, Jill M. Spoerke, Yuanyuan Xiao, Carol O’Brien, Heidi Savage, Teiko Sumiyoshi, Ling Fu, Hartmut Koeppen, Mark R. Lackner	2014	1
17	Nonmyeloablative Conditioning Regimen to Increase Engraftment of Gene-modified Hematopoietic Stem Cells in Young Rhesus Monkeys Molecular Therapy ·Alice F. Tarantal, Francesca Giannoni, J. Kayden Robinson, G. Vougiouka, Teiko Sumiyoshi, Po Hen Lin, Christoph Kahl, David Elashoff, Stan G. Louie, Donald B. Kohn	2012	21
18	Stable Transgene Expression in Primitive Human CD34 ⁺ Hematopoietic Stem/Progenitor Cells, Using the Sleeping Beauty Transposon System Human Gene Therapy ·Teiko Sumiyoshi, Nathalia Holt, Roger P. Hollis, Shundi Ge, Paula M. Cannon, Gay M. Crooks, Donald B. Kohn	2009	41
19	Transcription of the cpeBA and cpeCDE operons in wild type and green mutant strains of the cyanobacterium, Fremyella diplosiphon USF Scholarship Repository (University of San Francisco) ·Teiko Sumiyoshi	2003	1
20	CpeR is an activator required for expression of the phycoerythrin operon (cpeBA) in the cyanobacterium Fremyella diplosiphon and is encoded in the phycoerythrin linker‐polypeptide operon (cpeCDESTR) Molecular Microbiology ·John Cobley, A. Clay Clark, О.Г. Панфілов, Shinsuke Ito, Roger Shodeke, C Gosseries, Yin Chengquan, Faza 'Ainun Najah, Annelise Finegan Wasmoen, Teiko Sumiyoshi, M. H. Skikevych	2002	75

About Teiko Sumiyoshi

Teiko Sumiyoshi is a scholar working on Oncology, Hematology, Genetics, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 28 papers that have together received 549 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Multiple Myeloma Research and Treatments (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), CAR-T cell therapy research (4 papers), Colorectal Cancer Treatments and Studies (4 papers), Virus-based gene therapy research (3 papers) and RNA Interference and Gene Delivery (3 papers). The work is most often cited by research in Oncology (279 citations), Hematology (92 citations), Cancer Research (99 citations), Molecular Biology (275 citations) and Immunology (81 citations). Teiko Sumiyoshi has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Donald B. Kohn, Mark R. Lackner, Hartmut Koeppen, Garret M. Hampton, Priti S. Hegde, Erica Schleifman, Rachel Tam, A. Clay Clark, John Cobley and Simon J. Harrison. Their work appears in journals such as Blood, PLoS ONE, Molecular Therapy, Journal of Clinical Oncology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact